Announces First Blockchain-Enabled Natural Language Processing Platform For Quantified Biology

SAN FRANCISCO, Aug. 24, 2017 /PRNewswire/ — Coming out of stealth mode, Incorporated (“”) today announced the launch of its advanced natural language processing technology platform using the blockchain to timestamp its datasets and decentralize artificial intelligence. Envisioned and built by bright minds from Stanford and Cambridge Universities, is well-positioned to help healthcare companies improve patients’ care and experience by creating the most advanced natural language dialog system that generates insights from combined medical data.

“We are making it possible for lab tests to converse directly with patients by leveraging advanced artificial intelligence, medical data forensics, and the decentralized blockchain. We envision extensive possibilities for the use of this technology by doctors, patients, and medical institutions,” commented Walter De Brouwer, founder and chief executive officer of

Deloitte Life Sciences and Healthcare is working with to test its Robo-Hematology solution, which was unveiled on July 24, 2017 at Deloitte University in Dallas, Texas.

“’s AI-based doctors provide answers to health questions using an AI-powered platform,” said Rajeev Ronanki, Deloitte Consulting LLP principal of Life Sciences and Health Care. “Platforms like these open new possibilities for patients and medical organizations by providing more personalized, intelligent healthcare. We are excited to collaborate with and to be at the forefront of this technology.”

How Works is building a new platform for established medical companies to enable patients to have personalized, AI-powered conversations about their health at any time of day. Over the next twelve months, expects to roll out three natural language processing modules: Robo-Genomics, Robo-Hematology, and Robo-Anatomics, to the industry’s leading medical providers and payors.

Details about’s platform:

  1. Working with medical companies,’s AI technology is designed to use a decentralized, edge-learning network to develop insights based on personal data. An edge-learning network performs deep learning computations at the edge of the network or on a mobile device.
  2.’s AI technology personalizes conversations with patients on their health data via a mobile app, and is available to provide information 24/7.
  3. The patient can ask the AI questions such as “What should be my optimal Ferritin value based on my iron storage deficiency?” or “How can I decrease my cholesterol in the next 3 weeks?” or “Why was my glucose level over 100 and a week later it is at 93?” AI provides the answers and additional context for each answer.
  4. Patients can leverage conversations with the AI-powered robo-doctor to achieve better health outcomes from consultations with their physician.

According to the World Health Organization, there is a shortage of over seven million physicians, nurses, and other healthcare professionals worldwide, and the gap is widening. Doctors are challenged to respond to the growing needs of the population, while keeping abreast of the latest developments in medicine and healthcare. Further, training doctors, nurses, and other healthcare professionals is an arduous process that requires years of education and experience. Artificial intelligence can help address these challenges while improving patients’ care and experience. Digital Token Sale Details

To power its platform and incentivize the community, will be creating digital tokens, named Neurons (“NRNs”), based on the ERC-20 standard. will sell and issue Simple Agreements for Future Tokens (“SAFTs”), which will convert into NRNs upon the launch of the platform. SAFTs will initially be available through a pre-sale process that is expected to start on September 7, 2017. The crowdsale process is expected to start on September 28, 2017. The solicitation, offer, and sale of SAFTs will be conducted in a manner that is compliant with applicable securities laws and regulations, including Rule 506(c) of Regulation D. In the United States, only verified accredited investors will be eligible to purchase SAFTs.

The total number of NRN to be created will be based on the number of neurons in the human brain, 86 billion. Total of 860 million NRN will be created, with one NRN representing 100 neurons in the human brain. Approximately 37% of the total number of NRNs is expected to be sold in the SAFT offering. plans to use the funds raised from the sale of SAFTs to further develop its platform and technology.

About is helping healthcare companies to improve patients’ care and experience by creating the industry’s most advanced intelligent natural language processing platform that generates insights from medical data.’s team is teaching machines the language of biology and training the first generation of AI in natural language comprehension and computer vision. was founded by the entrepreneurial duo Walter and Sam De Brouwer in 2016. The Palo Alto, California, company has raised seed funding from Comet Labs, F50, Legend Star and S2 Capital, and has several prominent clients.

Forward Looking Statements

Certain information set forth in this press release contains “forward-looking information” under applicable securities laws. Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, (i) the projected performance of; (ii) the completion of, and the use of proceeds from, the sale of SAFTs; (iii) the expected development of’s business, projects, and joint ventures; (iv) the execution of the Company’s vision and growth strategy, including with respect to future global growth; (v) the sources and availability of third-party financing for’s projects; (vi) the completion of’s  projects that are currently underway, in development or otherwise under consideration; (vii)’s ability to launch a functional platform, which includes the related creation and issuance of NRNs; (viii) renewal of the Company’s current customer, supplier, and other material agreements; and (ix) the future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential purchasers of SAFTs the opportunity to understand management’s beliefs and opinions in respect of the future. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this press release are based upon what management believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.’s undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Securities Disclaimer

This press release is for informational purposes only and does not constitute an offer or solicitation to sell securities. Any such offer or solicitation will be made only by means that are in compliance with applicable securities and other laws, including Rule 506(c) of Regulation D. No information or opinions presented herein are intended to form the basis for any purchase decision, and no specific recommendations are intended. Accordingly this press release does not constitute investment advice or counsel or solicitation for investment in any security. This press release does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or any invitation to offer to buy or subscribe for, any securities, nor should it or any part of it form the basis of, or be relied on in any connection with, any contract or commitment whatsoever. expressly disclaims any and all responsibility for any direct or consequential loss or damage of any kind whatsoever arising directly or indirectly from: (i) reliance on any information contained in this press release, (ii) any error, omission or inaccuracy in any such information, and (iii) any action resulting therefrom.